Table 3 |
||||||
|
Subjective Improvement: Treatment Success Definition by Intervention |
||||||
|
Study |
Study Design |
Sample Size |
Study Population |
Comparator |
Success Evaluated (months) |
Success % |
|
|
||||||
|
Botulinum toxin type A |
||||||
|
Loch, Eur Urol Supp, 2003* [60] |
Open Label |
30, 30 |
NOAB, IOAB |
None |
8, 8 |
67, 67 |
|
Rapp, Urology, 2004 [61] |
Open Label |
35 |
IOAB |
None |
6 |
60 |
|
Grosse, Eur Urol, 2005 [62] |
Open Label |
66 |
NOAB |
None |
10 |
86.3 |
|
Rajkumar, BJU Int, 2005 [63] |
Open Label |
15 |
IOAB |
None |
1.5 |
93 |
|
Schulte-Baukloh, Eur Urol, 2005 [64] |
Open Label |
44 |
IOAB |
None |
3 |
86 |
|
Schmid, J Urol, 2006 [65] |
Open Label |
100 |
IOAB |
None |
3 |
88 |
|
Schulte-Baukloh, Neur Urodyn, 2006 [66] |
Open Label |
16 |
NOAB |
None |
6 |
100 |
|
Kuo, J Urol, 2007 [67] |
Open Label |
45 |
IOAB |
None |
3 |
80 |
|
|
||||||
|
Augmentation cystoplasty |
||||||
|
Edlund, Scand J Urol Nephrol, 2001 [68] |
Open Label |
25 |
IOAB |
None |
60 |
78 |
|
Barrington, Int Urogynecol J, 2006 [69] |
Open Label |
12 |
IOAB |
None |
12 |
83 |
|
Chartier-Kaslter, Spinal Cord, 2000 [43] |
Open Label |
17 |
NOAB |
None |
75.6 |
88.5 |
|
Quek, J Urol, 2003 [45] |
Open Label |
26 |
NOAB |
None |
96 |
96 |
|
Nomura, Spinal Cord, 2002 [70] |
Open Label |
11 |
NOAB |
None |
66 |
100 |
|
|
||||||
|
* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations. Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported. |
||||||
|
Campbell et al. BMC Urology 2009 9:18 doi:10.1186/1471-2490-9-18 |
||||||
